... BELLEVUE Wash. Aug. 7 /- SCOLR Pharma In...Daniel O. Wilds SCOLR Pharma's President and CEO said We arepleas...As reported during the period we received the FDA's response to ours...Total revenues which consist of royalty revenue from our collaboratio...

BELLEVUE, Wash., Aug. 7 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc.
(Amex: DDD) today reported financial results for the three and six months
ended June 30, 2008. The Company will host a live conference call today,
August 7, 2008, at 11:30 a.m. (Eastern Daylight Time).

Daniel O. Wilds, SCOLR Pharma's President and CEO, said, "We are
pleased with the significant progress made during the second quarter
maintaining a sharp focus on advancing our two lead product candidates,
supporting our corporate partnerships and collaborations, aggressively
managing our expenses, and assuring that we have sufficient operating
capital through the end of 2009.

As reported during the period, we received the FDA's response to our
special protocol assessment that provided further Phase III study design
clarity for our over-the-counter (OTC) 12-hour extended-release (ER)
ibuprofen product candidate. Subsequently, we incorporated the FDA's
suggestions in our study protocol and initiated this important pivotal
trial on June 30, 2008. In addition, we announced the submission of an
Abbreviated New Drug Application (ANDA) for our OTC 12-hour ER
pseudoephedrine product candidate in early August. We also announced the
buy-out of our corporate facility lease under which we will receive an
aggregate of $4.1 million. By continuing to focus spending on our lead
product candidates, limiting additional drug development initiatives to
those already partnered and in active collaborations, we expect that the
net proceeds from the lease buy-out and current financial resources
together with continuing expense management will be sufficient to fund our
operations through 2009. "

Total revenues, which consist of royalty revenue from our collaboration
agreements, decreased 34%, or $142,485 to $279,571 for the three months
ended June 30, 2008, compared to $422,056 for the same period in 2007. This
decrease is primarily due to lower royalty income from our relationship
with Perrigo. However, royalty income increased 5%, or $14,016 to $279,571
in the three months ended June 30, 2008, compared to $265,555 for the first
quarter of 2008 as Perrigo increased sales to a major national retailer.

Total revenues of $545,126 decreased 65% or $996,849 for the six months
ended June 30, 2008, compared to $1.5 million for the same period in 2007.
The higher total revenues for 2007 were primarily due to approximately
$795,000 of research and development fees and licensing revenues from an
agreement terminated in the first quarter of 2007.

Net loss increased less than 1%, or $1,380 to $2.1 million for the
three months ended June 30, 2008, compared to $2.1 million for the same
period in 2007. Net loss for the six months ended June 30, 2008, increased
2%, or $98,429 to $4.1 million compared with a net loss of $4.0 million for
the same period in 2007. The increased losses were primarily due to lower
revenues and other income, offset by lower operating costs.

Total operating expenses for the second quarter of 2008 decreased 7% to
$2.5 million compared to $2.7 million for the same period in 2007.
Operating expenses decreased 19% to $4.8 million for the six months ended
June 30, 2008 from $5.9 million for the same period in 2007. The decreases
in operating expenses were primarily due to reductions in advertising and
tradeshow expense, research and development, and outside services.

In May 2008, we entered into an agreement to terminate the existing
lease of our corporate facility for consideration of $4.1 million. Under
the terms of the agreement, $1.0 million was paid upon execution of the
agreement and the remaining $3.1 million is due when we vacate the
premises, at which time the amount will be recognized as a gain.

We had approximately $8.0 million in cash and cash equivalents, and
$564,000 in restricted cash as of June 30, 2008. In addition, we expect to
receive an additional $3.1 million in October 2008, related to our Lease
Termination Agreement. We believe that our cash, cash equivalents and
short- term investments will be sufficient to fund our operations at
planned levels through the end of 2009.

Conference Call

As previously announced, SCOLR Pharma will host a conference call on
August 7, 2008, at 11:30 a.m. (Eastern Daylight Time). Shareholders and
other interested parties may participate in the conference call by dialing
+1 888 680 0878 (domestic) or +1 617 213 4855 (international) and entering
access code 26733631, a few minutes before 11:30 a.m. ET on August 7, 2008.
The call will also be broadcast live on the Internet at
http://www.streetevents.com,http://www.fulldisclosure.com or http://www.scolr.com.

Based in Bellevue, Washington, SCOLR Pharma, Inc. is a specialty
pharmaceutical company. SCOLR Pharma's corporate objective is to combine
its formulation expertise and its patented CDT platform to develop novel
pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT
drug delivery platform is based on multiple issued and pending patents and
other intellectual property for the programmed release or enhanced
performance of active pharmaceutical ingredients and nutritional products.
For more information on SCOLR Pharma, please call 425.373.0171 or visit
http://www.scolr.com/.

This press release contains forward-looking statements (statements
which are not historical facts) within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements concerning
the adequacy of our capital resources to fund our operations. These
forward-looking statements involve risks and uncertainties, including
activities, events or developments that we expect, believe or anticipate
will or may occur in the future. A number of factors could cause actual
results to differ from those indicated in the forward-looking statements,
including our ability to successfully develop new formulations and complete
research and development, including pre-clinical and clinical studies, our
ability to raise additional funds, the continuation of arrangements with
our product development partners and customers, competition, government
regulation and approvals, and general economic conditions. For example, if
our clinical trials are not successful or take longer to complete than we
expect, we may not be able to develop and commercialize our products. And
we may not obtain regulatory approval for our products, which would
materially impair our ability to generate revenue. Additional assumptions,
risks and uncertainties are described in detail in our registration
statements, reports and other filings with the Securities and Exchange
Commission. Such filings are available on our website or at http://www.sec.gov.
You are cautioned that such statements are not guarantees of future
performance and that actual results or developments may differ materially
from those set forth in the forward-looking statements. We undertake no
obligation to publicly update or revise forward-looking statements to
reflect subsequent events or circumstance.

(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...

(Date:10/11/2017)... VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...

(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...

(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...